Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn

Chronological Source Flow
Back

AI Fusion Summary

Johnson & Johnson is in advanced talks to acquire Ollin Biosciences, a biotech firm focused on eye disease treatments, for up to $3.4 billion. Financial Times reports the deal is part of a broader surge of acquisitions in the biotechnology sector, highlighting J&J's strategic interest in expanding its pharmaceutical portfolio.
Community Comments
Loading updates...
0